What is a stock summary page? Click here for an overview.
Business Description
Mineralys Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US6031701013
Description
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.93 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1.8 | |||||
| 3-Year EPS without NRI Growth Rate | -0.2 | |||||
| 3-Year FCF Growth Rate | -6.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -2.94 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.44 | |||||
| 9-Day RSI | 54.05 | |||||
| 14-Day RSI | 58.18 | |||||
| 3-1 Month Momentum % | -22.31 | |||||
| 6-1 Month Momentum % | -16.3 | |||||
| 12-1 Month Momentum % | -22.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.02 | |||||
| Quick Ratio | 14.02 | |||||
| Cash Ratio | 13.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -113 | |||||
| Shareholder Yield % | -12.32 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -69.05 | |||||
| ROA % | -63.89 | |||||
| ROIC % | -6064.9 | |||||
| 3-Year ROIIC % | -4548.93 | |||||
| ROC (Joel Greenblatt) % | -42398.19 | |||||
| ROCE % | -74.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.91 | |||||
| Price-to-Tangible-Book | 3.91 | |||||
| EV-to-EBIT | -4.24 | |||||
| EV-to-Forward-EBIT | -2.55 | |||||
| EV-to-EBITDA | -4.24 | |||||
| EV-to-Forward-EBITDA | -2.56 | |||||
| EV-to-FCF | -4.9 | |||||
| Price-to-Net-Current-Asset-Value | 3.92 | |||||
| Price-to-Net-Cash | 4.08 | |||||
| Earnings Yield (Greenblatt) % | -23.58 | |||||
| FCF Yield % | -17.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLYS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mineralys Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.64 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 28.92 | ||
| 14-Day RSI | 58.18 | ||
| 14-Day ATR ($) | 1.334158 | ||
| 20-Day SMA ($) | 13.6645 | ||
| 12-1 Month Momentum % | -22.07 | ||
| 52-Week Range ($) | 8.241 - 18.38 | ||
| Shares Outstanding (Mil) | 62.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mineralys Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mineralys Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mineralys Therapeutics Inc Frequently Asked Questions
What is Mineralys Therapeutics Inc(MLYS)'s stock price today?
The current price of MLYS is $15.00. The 52 week high of MLYS is $18.38 and 52 week low is $8.24.
When is next earnings date of Mineralys Therapeutics Inc(MLYS)?
The next earnings date of Mineralys Therapeutics Inc(MLYS) is 2025-05-09 Est..
Does Mineralys Therapeutics Inc(MLYS) pay dividends? If so, how much?
Mineralys Therapeutics Inc(MLYS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers